Carmustine
| Evidence Level: L5 | Predicted Indications: 87 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Carmustine |
| DrugBank ID | DB00262 |
| Brand Names (EU) | Carmustine medac (previously Carmustine Obvius) |
| Evidence Level | L5 |
| Predicted Indications | 87 |
| Top Prediction Score | 98.92% |
Approved Indication (EMA)
Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haema
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | lymphosarcoma | 98.92% | DL |
| 2 | lymph node cancer | 98.49% | DL |
| 3 | astrocytoma (excluding glioblastoma) | 97.13% | DL |
| 4 | adult astrocytic tumour | 96.88% | DL |
| 5 | cauda equina neoplasm | 96.70% | DL |
| 6 | reticulum cell sarcoma | 96.20% | DL |
| 7 | lymphoma, non-Hodgkin, familial | 95.96% | DL |
| 8 | childhood cerebral astrocytoma | 94.61% | DL |
| 9 | B-cell neoplasm | 94.10% | DL |
| 10 | lymphoma | 94.01% | DL |
| 11 | subependymal giant cell astrocytoma | 93.23% | DL |
| 12 | astrocytic tumor | 93.10% | DL |
| 13 | interdigitating dendritic cell sarcoma | 92.42% | DL |
| 14 | non-Hodgkin lymphoma | 91.90% | DL |
| 15 | colon adenocarcinoma | 91.65% | DL |
| 16 | subcutaneous panniculitis-like T-cell lymphoma | 90.68% | DL |
| 17 | cerebellar astrocytoma | 89.98% | DL |
| 18 | T-cell/histiocyte rich large B cell lymphoma | 89.60% | DL |
| 19 | low grade astrocytic tumor | 89.42% | DL |
| 20 | childhood astrocytic tumor | 89.33% | DL |
Showing top 20 of 87 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.